Language

English

Publication Date

4-1-2026

Journal

Journal of Medical Virology

DOI

10.1002/jmv.70931

PMID

41989210

PMCID

PMC13085960

PubMedCentral® Posted Date

4-16-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Nearly all cervical cancer cases are caused by high-risk human papillomavirus (hrHPV) infections. The World Health Organization recommends screening for hrHPV using nucleic acid amplification tests (NAATs) that detect hrHPV DNA or mRNA. Lack of access to affordable, point-of-care screening tests in resource-limited settings leads to women presenting with advanced-stage cervical cancer, with many dying of the disease. There is a significant need to develop point-of-care NAATs to improve screening and early detection. Because access to real clinical samples is limited, initial evaluation of NAATs is often performed using contrived samples created using some combination of extracted hrHPV DNA and/or cultured hrHPV-positive cells. When mock samples do not adequately recapitulate the contents of clinical cervicovaginal samples, it can delay clinical translation of potentially promising assays. To improve the value of contrived samples, we characterized the composition of 32 hrHPV DNA-positive cervicovaginal clinical samples. We also describe a simple method to generate contrived samples that mimic the diversity of clinical cervicovaginal samples, and test them using the methods used to characterize the clinical samples. Results show that the hrHPV DNA content of cervicovaginal samples varies by approximately eight orders of magnitude and spans from 100% linear integrated DNA to 100% circular non-integrated DNA, that the concentration of hrHPV mRNA also varies by nearly nine orders of magnitude between patient samples, and that the concentration of potential inhibitors such as hemoglobin varies by more than three orders of magnitude. hrHPV DNA and mRNA extracted from contrived samples exhibited expected patterns of DNA quantity, DNA conformation, and mRNA quantity. Altogether, the protocols described here to generate mock samples can help NAAT developers optimize test performance prior to clinical evaluation, potentially improving test performance and reducing time to deployment.

Keywords

Female, Humans, Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, Human Papillomavirus Viruses, Vagina, Cervix Uteri, DNA, Viral, Molecular Diagnostic Techniques, Papillomaviridae, Mass Screening

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.